We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy.
Shutting Down Pain
Xenon featured in Genentech’s Big Ideas animated short
June 27, 2017 – Xenon to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN
June 27, 2017 – Teva and Xenon Announce Phase II Study of Topical TV-45070 in Patients with Post-Herpetic Neuralgia (PHN) Did Not Meet Primary Endpoint
June 2, 2017 – Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
May 9, 2017 – Xenon Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update